Share your videos with the world

Sign Up | Log In | Help  

   
 
Search // lesions
Results 1-4 of 4 for ' lesions ' (0 seconds)
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
Categories // Business 
Added: 2981 days ago by MultiVuVideos
Runtime: 2m25s | Views: 634 | Comments: 2
Not yet rated
 

 

 

PicoWay incorporates the highest peak power and the shortest pulse durations of any aesthetic laser in the market. The combination of these two technological breakthroughs creates the strongest photo-mechanical impact, which enables the most safe and effective fracturing of tattoo ink or pigmentation. The revolutionary PicoWay technology is integrated into a proven, reliable Candela™ platform which ensures superior performance and low cost of ownership. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
Categories // Business 
Added: 2981 days ago by MultiVuVideos
Runtime: 1m31s | Views: 576 | Comments: 2
Not yet rated
 

 

 

C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA). To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
Categories // News and Politics 
Added: 4557 days ago by MultiVuVideo
Runtime: 4m15s | Views: 5231 | Comments: 0
Not yet rated
 

 

 

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Added: 4563 days ago by MultiVuVideos
Runtime: 2m16s | Views: 6026 | Comments: 1
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2022 ClipMoon.com. All rights reserved.